2019
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals Of Oncology 2019, 30: 310-316. PMID: 30566587, PMCID: PMC6386026, DOI: 10.1093/annonc/mdy541.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalAspirinCase-Control StudiesCohort StudiesEndometrial NeoplasmsFemaleFollow-Up StudiesHumansPrognosisRisk FactorsUnited StatesConceptsNon-aspirin nonsteroidal anti-inflammatory drugsNonsteroidal anti-inflammatory drugsEndometrial Cancer ConsortiumEndometrial cancerAnti-inflammatory drugsObese womenOdds ratioCancer ConsortiumStudy-specific odds ratiosLogistic regressionStandard-dose aspirinUse of aspirinUse of acetaminophenConfidence intervalsTimes/weekCase-control studyRisk of cancerMixed-effects logistic regressionLow-dose formulationsLeast weekly useNormal weightPooled analysisInverse associationStratified analysisReduced risk
2018
Re: NSAID Use and Pancreatic Cancer Risk
Risch HA. Re: NSAID Use and Pancreatic Cancer Risk. Gastroenterology 2018, 155: 931. PMID: 30092188, DOI: 10.1053/j.gastro.2017.12.053.Peer-Reviewed Original Research
2017
Low-Dose Aspirin and Pancreatic Cancer Risk—Reply
Risch HA. Low-Dose Aspirin and Pancreatic Cancer Risk—Reply. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 1155-1156. PMID: 28634185, PMCID: PMC5500422, DOI: 10.1158/1055-9965.epi-17-0208.Peer-Reviewed Original ResearchAspirin and Pancreatic Cancer—Response
Risch HA. Aspirin and Pancreatic Cancer—Response. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 979-979. PMID: 28506963, PMCID: PMC5457337, DOI: 10.1158/1055-9965.epi-17-0099.Peer-Reviewed Original ResearchAnti-Inflammatory Agents, Non-SteroidalAspirinHumansInhibitor of Apoptosis ProteinsPancreatic NeoplasmsSurvivinUse of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Ness R, Edwards R, Jensen A, Kjær S, Høgdall E, Berchuck A, Cramer D, Terry K, Poole E, Bandera E, Paddock L, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Pearce C, Wu A, Pike M, Webb P. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal Of Cancer 2017, 116: 1223-1228. PMID: 28350790, PMCID: PMC5418444, DOI: 10.1038/bjc.2017.68.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdultAgedAnalgesicsAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAspirinDisease-Free SurvivalFemaleHumansMiddle AgedOvarian NeoplasmsProportional Hazards ModelsRisk FactorsConceptsNonsteroidal anti-inflammatory drugsDisease-specific survivalOvarian cancer survivalAnalgesic useCancer survivalOvarian cancerInvasive epithelial ovarian cancerCommon analgesic medicationsPost-diagnosis usePre-diagnosis useRegular analgesic useEpithelial ovarian cancerOvarian Cancer Association ConsortiumAnti-inflammatory drugsAnalgesic medicationOverall survivalImproved survivalPooled analysisCommon analgesicsSurvival advantageConsortium studyClear associationCancerSurvivalFurther investigation
2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinCase-Control StudiesCyclooxygenase 2 InhibitorsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMaleMiddle AgedPancreatic NeoplasmsQueenslandSmokingConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studies
2014
Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer
Streicher SA, Yu H, Lu L, Kidd MS, Risch HA. Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 1254-1263. PMID: 24969230, PMCID: PMC4091763, DOI: 10.1158/1055-9965.epi-13-1284.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalAspirinCase-Control StudiesFemaleHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsAspirin usePancreatic cancerLong-term aspirin useLow-dose aspirinCase-control studyCalendar time periodTime of interviewRisk-benefit analysisAspirin regimenCardiovascular diseaseReduced riskYear of interviewPossible associationCancerConnecticut StudyRegular useAspirinRiskCase frequencySignificant relationshipYearsRegimenComplicationsPrognosisMortalityAspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Group T, Risch H, Rossing M, Doherty J, Goodman M, Lurie G, Kjær S, Hogdall E, Jensen A, Cramer D, Terry K, Vitonis A, Bandera E, Olson S, King M, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pearce C, Pike M, Berchuck A, Schildkraut J, Wentzensen N, Consortium O. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal Of The National Cancer Institute 2014, 106: djt431. PMID: 24503200, PMCID: PMC3924755, DOI: 10.1093/jnci/djt431.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAspirinAustraliaCarcinoma, Ovarian EpithelialCase-Control StudiesData CollectionDenmarkDrug Administration ScheduleFemaleHumansIncidenceLogistic ModelsNeoplasms, Glandular and EpithelialOdds RatioOvarian NeoplasmsProtective AgentsRiskUnited KingdomUnited StatesConceptsNonaspirin nonsteroidal anti-inflammatory drugsNonaspirin NSAIDsInvasive epithelial ovarian cancerNonsteroidal anti-inflammatory drugsLow-dose aspirinEpithelial ovarian cancerOvarian cancerAnti-inflammatory drugsAspirin useAcetaminophen useOdds ratioPopulation-based case-control studyDaily aspirin usersRegular aspirin useOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumHigh-dose usageDose of useAspirin regimenAnalgesic useAspirin usersCardiovascular eventsDose aspirinCase patients
2011
Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis
Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow W, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology 2011, 142: 442-452.e5. PMID: 22108196, PMCID: PMC3488768, DOI: 10.1053/j.gastro.2011.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalAustraliaCanadaCase-Control StudiesCohort StudiesEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansLogistic ModelsMaleMiddle AgedOdds RatioRisk AssessmentRisk FactorsStomach NeoplasmsTime FactorsUnited StatesYoung AdultConceptsNonsteroidal anti-inflammatory drugsEsophagogastric junctional adenocarcinomaRisk of EACNSAID useEsophageal adenocarcinomaPooled analysisOdds ratioEsophagogastric junctionNonaspirin nonsteroidal anti-inflammatory drugsStudy-specific odds ratiosRandom-effects meta-analysis modelEffects meta-analysis modelPrevention of adenocarcinomaUse of aspirinSignificant reduced riskPopulation-based studyConfidence intervalsAnti-inflammatory drugsDuration of useEsophageal Adenocarcinoma ConsortiumMeta-analysis modelLogistic regression modelsJunctional adenocarcinomaMedication typeEAC risk
2008
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes & Control 2008, 20: 361-368. PMID: 18989634, PMCID: PMC2726999, DOI: 10.1007/s10552-008-9250-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAnti-Inflammatory Agents, Non-SteroidalBody Mass IndexCarcinoma, Squamous CellCardiaCase-Control StudiesConfidence IntervalsEsophageal NeoplasmsGastroesophageal RefluxHumansImmunohistochemistryLogistic ModelsMiddle AgedMulticenter Studies as TopicOdds RatioPopulation SurveillanceRisk FactorsSmokingStomach NeoplasmsTumor Suppressor Protein p53United StatesConceptsBody mass indexNon-steroidal anti-inflammatory drugsGastroesophageal reflux diseaseRisk factorsP53 overexpressionGastric cancerCigarette smokingReflux diseaseMass indexNon-steroidal anti-inflammatory drug useTumor subtypesPopulation-based case-control studyAnti-inflammatory drug useNon-cardia gastric adenocarcinomaGastro-esophageal reflux diseaseLarger body mass indexNon-cardia gastric cancerEsophageal squamous cell carcinomaTumor p53 overexpressionRisk factor profileSquamous cell carcinomaRisk of subtypesCase-control studyAnti-inflammatory drugsP53 protein overexpression
2004
Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1A Population-Based Study
Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni JF, Weinstein IB, Hibshoosh H. Nonsteroidal Anti-inflammatory Drug Use Associated with Reduced Incidence of Adenocarcinomas of the Esophagus and Gastric Cardia that Overexpress Cyclin D1A Population-Based Study. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 34-39. PMID: 14744730, DOI: 10.1158/1055-9965.epi-03-0198.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAnti-Inflammatory Agents, Non-SteroidalConfidence IntervalsCyclin D1Esophageal NeoplasmsFemaleHumansLife StyleMaleMiddle AgedPopulation SurveillancePrevalenceRisk FactorsStomach NeoplasmsSurveys and QuestionnairesUnited StatesConceptsCyclin D1 statusOdds ratioCyclin D1NSAID useGastric cardiaRisk factorsCase groupD1 tumorsNonsteroidal anti-inflammatory drug usePopulation-based case-control studyAnti-inflammatory drug useMultivariate-adjusted odds ratioEsophageal squamous cell carcinomaNoncardia gastric adenocarcinomaUse of aspirinSquamous cell carcinomaGastric cancer patientsCase-control studyGastric cardia adenocarcinomaCigarette smokingCell carcinomaCancer patientsGastric adenocarcinomaEsophageal adenocarcinomaReduced incidence